Download PDF
XX Die Zeitschrift für Frauen in der Medizin 2012; 1(1): 18-22
DOI: 10.1055/s-0032-1306222
Genderperspektiven
© Georg Thieme Verlag Stuttgart · New York

Aspirin ist nicht gleich Aspirin – Geschlechterunterschiede in der Pharmakologie

Petra Thürmann
Further Information

Publication History

Publication Date:
06 March 2012 (online)

    Permissions and Reprints

Frauen und Männer beschreiben nicht nur unterschiedliche Symptome, wenn sie krank sind. Sie sprechen auch unterschiedlich auf Medikamente an. Lesen Sie hier, wie diese Differenzen zwischen den Geschlechtern entstehen und weshalb es wichtig ist, sie in der Forschung zu berücksichtigen.

 

  • Literatur

  • 1 Patel H, Rosengren A, Ekman I. Symptoms in acute coronary syndromes: does sex make a difference?. Am Heart J 2004; 148: 27-33
    CrossrefSearch in Google Scholar
  • 2 Kim JS, Nafziger AN. Is it sex or is it gender?. Clin Pharmacol Ther 2000; 68: 1-3
    CrossrefSearch in Google Scholar
  • 3 Thürmann PA. Arzneimittelanwendung bei Frauen: ”off-label“?. Psychopharmakotherapie 2007; 14: 237-242
    Search in Google Scholar
  • 4 Haack S, Seeringer A, Thürmann PA et al. Sex-specific differences of psychotropic drugs: genes or gender?. Pharmacogeneomics 2009; 10: 1511-1526
    Search in Google Scholar
  • 5 Thürmann P, Janhsen K, Werner U et al. Sex-differences in the rate of adverse drug reactions associated with diuretics. Düsseldorf: German Medical Science GMS Publishing House; Im Internet: http://www.egms.de/en/meetings/gaa2008/08gaa11.shtml Stand 12.12.2011
    Search in Google Scholar
  • 6 Chen Z, Vaughn DA, Fanestil DD. Influence of gender on renal thiazide diuretic receptor density and response. J Am Soc Nephrol 1994; 5: 1112-1119
    Search in Google Scholar
  • 7 Brandoni A, Villar SR, Torres AM. Gender-related differences in the pharmacodynamics of furosemide in rats. Pharmacology 2004; 70: 107-112
    CrossrefSearch in Google Scholar
  • 8 Werner D, Werner U, Meybaum A et al. Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. Clin Pharmacokinet 2008; 47: 323-332
    CrossrefSearch in Google Scholar
  • 9 Thürmann PA, Hompesch BC. Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther 1998; 36: 586-590
    Search in Google Scholar
  • 10 Wolbold R, Klein K, Burk O et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003; 38: 978-988
    CrossrefSearch in Google Scholar
  • 11 Cotreau MM, Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cyrochrome P450 3A substrates. Clin Pharmacokinet 2005; 44: 33-60
    CrossrefPubMedSearch in Google Scholar
  • 12 Luzier AB, Killian A, Wilton JH et al. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharm Ther 1999; 66: 594-601
    Search in Google Scholar
  • 13 Thürmann PA, Haack S, Werner U et al. Tolerability of beta-blockers metabolized via cytochrome P450 2D6 is sex-dependent. Clin Pharmacol Ther 2006; 80: 551-553
    CrossrefSearch in Google Scholar
  • 14 Niesters M, Dahan A, Kest B. Do sex differences exist in opioid analgesia? A systematic review and meta-analysis of human experimental and clinical studies. Pain 2011; 151: 61-68
    Search in Google Scholar
  • 15 Kornstein SG, Sloan DM, Thase ME. Gender-differences in depression and treatment response. Psychopharmacol Bull 2002; 36: 99-112
    Search in Google Scholar
  • 16 Martenyi F, Dossenbach M, Mraz K et al. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 2001; 11: 227-232
    CrossrefSearch in Google Scholar
  • 17 Ridker PM, Cook NR, Lee I-M et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-1304
    CrossrefSearch in Google Scholar
  • 18 Berger J, Roncaglioni MC, Avanzini F et al. Aspirin for the primary prevention of cardiovascular events in women and men. JAMA 2006; 295: 306-313
    CrossrefSearch in Google Scholar
  • 19 Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347: 1403-1411
    CrossrefSearch in Google Scholar
  • 20 Schmiedl S, Szymanski J, Rottenkolber M et al. Fingerhut – ein alter Hut? Eine Analyse stationärer Aufnahmen durch digitalisassoziierte unerwünschte Arzneimittelwirkungen. Med Klinik 2007; 102: 603-611
    CrossrefSearch in Google Scholar
  • 21 Martin R, Biswas PN, Freemantle SN et al. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 1998; 46: 505-511
    CrossrefSearch in Google Scholar
  • 22 Kubota K, Kubota N, Pearce GL et al. ACE-inhibitor-induced cough, an adverse drug reaction unrecognised for several years: studies in Prescription-Event Monitoring. Eur J Clin Pharmacol 1996; 49: 431-437
    CrossrefSearch in Google Scholar
  • 23 Drici MD, Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001; 24: 575-585
    CrossrefSearch in Google Scholar
  • 24 Kahn SE, Zinman B, Lachin JM et al. Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-Associated Fractures in Type 2 Diabetes. Diabetes Care 2008; 31: 845-851
    CrossrefSearch in Google Scholar
  • 25 Grey A, Bolland M, Gamble G et al. The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Endocrinol Metabol 2007; 92: 1305-1310
    Search in Google Scholar
  • 26 Tsang W, Alter DA, Wijeysundera HJ. The impact of cardiovascular disease prevalence on women's enrollment in landmark randomized cardiovascular trials: a systematic review. J Gen Intern Med ohne Seitenzahl 2011; [Epub ahead of print]
    Search in Google Scholar
  • 27 FDA. Evelyn B, Toigo T, Banks D et al. Women's participation in clinical trials and gender-related labeling. A review of new molecular entities approved 1995–1999 (24.08.2001). Im Internet: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ParticipatinginClinicalTrials/ucm197788.htm Stand 12.12.2011
    Search in Google Scholar
  • 28 Fleisch J, Fleisch MC, Thürmann PA. Women in early-phase clinical drug trials: Have things changed over the past 20 years?. Clin Pharmacol Ther 2005; 78: 445-452
    CrossrefSearch in Google Scholar
  • 29 Tenter U, Thürmann PA. References to sex-specific differences of drug effects in german SPCs for new entities from 1999 – 2004. Int J Clin Pharmacol Ther 2006; 44 (abstr.)
    Search in Google Scholar